gdc
FDA Approvals, News & UpdatesLymphoma

FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

In July 2020, the FDA approved Monjuvi as a new treatment option for patients with diffuse large B-cell lymphoma whose disease progressed after receiving other therapies.
October 2020 Vol 6 No 5

In July 2020, the FDA approved Monjuvi (tafasitamab-cxix; from Incyte and MorphoSys US), a CD19-directed antibody, for use in combination with Revlimid (lenalidomide), for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL for short) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for a transplant.

“Today’s FDA decision offers new hope for patients with this aggressive form of DLBCL who progressed during or after first-line therapy,” said Professor Gilles Salles, MD, Chair of the Clinical Hematology Department, University of Lyon, France.

The FDA approval of Monjuvi was based on the results of a phase 2, open-label, multicenter, single-arm clinical trial. All patients in the study had relapsed or refractory DLBCL and received treatment with Monjuvi, in combination with Revlimid.

Overall, 55% of the patients responded to treatment with the drug combination, including 37% of patients who had a complete response (no sign of cancer) and 18% of patients who had a partial response. The average duration of response was 21.7 months.

The most common side effects reported with Monjuvi were neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, fever, swelling (edema), respiratory tract infection, and decreased appetite.

For eligible patients who need financial assistance, Incyte and MorphoSys US offer a patient support program called My Mission Support.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLung Cancer
Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer.
FDA Approvals, News & UpdatesLung Cancer
Retevmo First Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy.
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
FDA Approvals, News & UpdatesLymphoma
Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
The FDA approved Tecartus as the first gene therapy (or CAR T-cell therapy) for patients with mantle-cell lymphoma, a rare type of non-Hodgkin lymphoma, that progressed after previous therapies.
Last modified: November 17, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country